Hillhurst Biopharmaceuticals, a San Diego, CA-based clinical stage biopharmaceutical company, raised an undisclosed amount in Seed funding.
The round was led by Friedman Bioventure Fund with participation from new and existing investors.
The company intends to use the funds to accelerate its Phase 2a clinical studies in sickle cell disease and in a second clinical indication.
Led by CEO Andrew Gomperts, Hillhurst Bio is a clinical stage company focused on its proprietary GLASS™ platform, which enables novel drug products based on therapeutic gases that, up until now, have been limited by inhaled delivery, including a pipeline of novel liquid therapeutic candidates intended to treat patients with sickle cell disease, Parkinson’s disease, and acute pain.
Its lead product, HBI-002, is an oral drug product candidate of low dose CO, with an administration route designed to enable chronic use in a home setting for patients suffering from sickle cell disease. Other potential disease targets are conditions associated with inflammation and cell death such as Parkinson’s disease.
FinSMEs
20/12/2023